COGTライブシグナル | Getagraph.comで利益を最大化

売る 104996 min ago

@ $8.60

発行日: 15 2月 2024 @ 05:09

リターン: -30.00%

前回のシグナル: 2月 15 - 02:47

前回のシグナル: 買う

リターン: -2.05 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	912 095
平均出来高	2.15M
時価総額	575.59M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.500 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.49
ATR14	$0.00500 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferrante Karen Jean	Buy	3 213	Stock Option (Right to Buy)
2024-03-28	Fairmount Funds Management Llc	Buy	286 851	Common Stock
2024-03-28	Fairmount Funds Management Llc	Buy	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	286 851	Common Stock

INSIDER POWER
88.06
Last 97 transactions
Buy: 19 542 341 \| Sell: 1 316 263

ボリューム相関

長: -0.11 (neutral)

短: -0.48 (neutral)

Signal:(56.59) Neutral

Cogint Inc. 相関

10 最も正の相関
NWL	0.911
CPIX	0.903
PRAX	0.9
CNDT	0.891
EWTX	0.89
QMCO	0.887
AQB	0.886
AVDX	0.886
SRTS	0.885
CHB	0.885

10 最も負の相関
PPBT	-0.881
FIZZ	-0.864
EPZM	-0.833
SNCR	-0.822
XOG	-0.821
TYHT	-0.816
LEDS	-0.805

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Cogint Inc. 相関 - 通貨/商品

-0.17
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.44
( neutral )

Cogint Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2023
収益:	$0
総利益:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2022
収益:	$0
総利益:	$-5.88M (0.00 %)
EPS:	$-2.26

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.814

Financial Reports:

No articles found.

Cogint Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.